Register to receive a free synopsis and brochure. Browse the Report Library
Numerous top dental implant companies in the United States are looking to increase their share of this growing market. In fact, there are over 35 competitors vying for position in this $1 billion-plus United States market. The three most dominant are Nobel Biocare, Straumann and Dentsply Sirona.
Nobel Biocare led the U.S. market in 2018, acquiring the leading position in the dental implant, final abutment and dental implant instrument kit segments. The company also had a presence in the treatment planning software and surgical guides segments. Its success in the dental implant market is largely due to the strong growth rates of its NobelActive® products. Nobel Biocare is expected to maintain growth in its implant sales, partly because of its entry into the dental regenerative industry.
Like Nobel Biocare, Straumann performs well in the U.S. dental implant fixture, final abutment and instrument kits markets. It also has a minor presence in the treatment planning software and surgical guides segments. Thus, Straumann is the second-leading competitor in the U.S. dental implant market, and is expected to continue growing its share of that market in years to come. Straumann has also pursued an ambitious acquisition strategy in the implant market. For example, in 2015, the company purchased Neodent, Brazil’s leading implant company.
The third-leading competitor in the U.S. dental implant market was Dentsply Sirona. The company offers a comprehensive line of implants and materials, and the Astra Tech Implant System™ was its main business driver. In 2016, Dentsply Sirona acquired MIS Implants, an Israeli company with a leading position in the value implant segment. Acquisitions like this, as well as mergers, are expected to aid the company’s position in the competitive landscape. However, it has lagged behind other premium implant companies in terms of market growth since the MIS Implants acquisition.
Zimmer Biomet, BioHorizons and Implant Direct were all top dental implant companies in the United States, each having a 7% or higher share of the market in 2018.
Zimmer Biomet was the fourth-leading competitor in the U.S. dental implant market in 2018. The company’s main portfolio of implant systems includes the following product lines: T3®, 3.1mmD Eztetic™, Tapered Screw Vent®, OSSEOTITE®, Trabecular Metal™ and LOCATOR® Overdenture Dental Implants System.
The implant market is largely dominated by premium products. Therefore, BioHorizons’ share in the value segment translates into a smaller portion of the overall U.S. implant market. However, the company’s higher price point, relative to other value implant brands, has contributed to its leading revenue share. Moreover, as the value segment is expected to demonstrate relatively high growth, BioHorizons is expected to experience significant growth in terms of sales.
In 2018, Implant Direct was the sixth-leading competitor in the U.S. dental implant market. The growing trend towards more value and discounted implants has greatly improved company sales. However, Implant Direct’s relatively low price in the market limits its overall market share.
HIOSSEN was the seventh-leading market competitor in 2018. The company is the North American subsidiary of Osstem Implant, which is the leading dental implant manufacturer in the South Korean and Asia-Pacific markets.
This company held a slightly smaller share than HIOSSEN in U.S. dental implant market. However, MIS Implants did benefit from the growing popularity of the value implant segment. MIS’ internally connected implant products accounted for most of its sales. The company was acquired by Dentsply Sirona in 2018, and thus, this premium implant company gained a foothold in the value implant market.
While the company has been a top contender in its domestic South Korean market for many years, where its implants are used in more than 6,000 procedures per month, it has recently begun to experience significant growth and increased adoption in the U.S.
In 2018, ACE Surgical maintained a modest share of the overall U.S. dental implant market. The company offers a series of implant fixtures, with those belonging to the Infinity family of products being its most profitable implant offering.
Bicon is commonly known for its specialty implants, and users of Bicon implants like them because they are simple, user-friendly and offered at a decent price. Customers have also remained committed to Bicon implants because clinical studies performed on the company’s products have proved that they are reliable and yield positive outcomes.
Anatomage held a small share of the U.S. dental implant market, due to its successful treatment planning software and surgical guide business. Anatomage does not offer a dental implant product, but instead solely specializes in treatment planning for implants and related surgical guide protection.
Dental Wings (Straumann)
Dental Wings is a leading provider of digital dentistry. In 2017, Straumann increased its ownership of Dental Wings from 55% to 100%. This, in turn, has helped the company gain access to a large customer base for dental implants. Its CoDiagnostiX™ software has grown in popularity, and in 2018 the company held a notable share of the treatment planning software market.
Blue Sky Bio
Blue Sky Bio is one of several foreign brands that dominated the discount or mini implant fixture segments in the U.S. dental implant market in 2018.
These companies, and 20-plus others, accounted for almost 10% of the overall market. Thus, making a notable part of the market highly fragmented.